Kymera Therapeutics, Inc. (KYMR) Key Metrics
KYMR valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $8.62B
- Enterprise value
- $8.98B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 82.1 10-yr median 53.0
- Price / book
- 6.4 10-yr median 4.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.98
KYMR key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsKYMR valuation Price multiples at each fiscal year-end price.
KYMR returns How much profit the business earns on the capital it uses.
KYMR per-share figures Results divided by the shares outstanding at year-end.
KYMR financial health Debt, liquidity and how easily interest is covered.
KYMR efficiency & capital use Working capital cycle and where the cash goes.
KYMR valuation history
KYMR returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
KYMR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
KYMR price vs earnings per share
KYMR key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $6.57B | $3.02B | $1.49B | $1.35B | $3.05B | $2.76B | — | — |
| Enterprise value | $5.80B | $2.62B | $1.20B | $956.3M | $2.62B | $2.48B | — | — |
| Price / sales | 167.5 | 64.1 | 18.9 | 28.7 | 41.8 | 81.2 | — | — |
| Price / book | 4.2 | 3.6 | 3.8 | 2.7 | 6.6 | 9.7 | — | — |
| Price / free cash flow | — | — | — | — | — | 35.0 | — | — |
| Price / operating cash flow | — | — | — | — | — | 31.3 | — | — |
| EV / sales | 148.0 | 55.6 | 15.2 | 20.4 | 36.0 | 73.0 | — | — |
| EV / free cash flow | — | — | — | — | — | 31.4 | — | — |
| Earnings yield | −4.7% | −7.4% | −9.9% | −11.5% | −3.3% | −1.7% | — | — |
| Free cash flow yield | −3.6% | −6.9% | −9.2% | −11.6% | −4.3% | 2.9% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $77.81 | $40.23 | $25.46 | $24.96 | $63.49 | $62.00 | — | — |
| Per share | ||||||||
| Revenue per share | $0.46 | $0.63 | $1.35 | $0.87 | $1.52 | $0.76 | $0.07 | $0.00 |
| Earnings per share | −$3.69 | −$2.98 | −$2.52 | −$2.87 | −$2.09 | −$1.02 | −$0.93 | −$0.48 |
| Operating cash flow per share | −$2.76 | −$2.59 | −$1.76 | −$2.84 | −$2.69 | $1.98 | $0.40 | −$0.40 |
| Free cash flow per share | −$2.78 | −$2.76 | −$2.35 | −$2.89 | −$2.72 | $1.77 | $0.39 | −$0.43 |
| Cash per share | $10.05 | $6.51 | $6.42 | $7.55 | $9.22 | $6.65 | $2.07 | $0.93 |
| Book value per share | $18.72 | $11.14 | $6.77 | $9.09 | $9.58 | $6.37 | −$1.67 | −$0.77 |
| Tangible book value per share | $18.72 | $11.14 | $6.77 | $9.09 | $9.58 | $6.37 | −$1.67 | −$0.77 |
| Capex per share | $0.02 | $0.17 | $0.59 | $0.05 | $0.03 | $0.20 | $0.01 | $0.03 |
| Debt per share | $0.97 | $1.17 | $1.45 | $0.32 | $0.37 | $0.40 | $0.48 | $0.02 |
| Shares outstanding | 84.4M | 75.0M | 58.4M | 53.9M | 48.0M | 44.6M | 44.5M | 44.5M |
| Change in shares outstanding | +12.5% | +28.6% | +8.2% | +12.4% | +7.7% | +0.1% | 0.0% | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −25.8% | −36.4% | −33.2% | −32.6% | −27.0% | −43.5% | — | — |
| Return on invested capital (ROIC) | −44.2% | −76.6% | −127.5% | −188.0% | −388.7% | — | — | — |
| Return on assets (ROA) | −22.9% | −28.8% | −24.9% | −25.6% | −18.3% | −15.1% | −51.3% | −48.5% |
| Return on tangible assets | −17.9% | −22.9% | −25.5% | −25.7% | −16.5% | −9.4% | −35.4% | −48.5% |
| Free cash flow margin | −597.8% | −440.5% | −174.7% | −333.0% | −179.2% | 232.2% | 592.1% | — |
| Financial health | ||||||||
| Total debt | $82.3M | $87.8M | $84.7M | $17.3M | $18.0M | $18.0M | $21.2M | $695,000 |
| Cash & short-term investments | $848.3M | $488.7M | $374.9M | $407.2M | $442.4M | $296.2M | $92.0M | $41.3M |
| Net debt | −$766.0M | −$401.0M | −$290.2M | −$389.8M | −$424.5M | −$278.2M | −$70.8M | −$40.6M |
| Debt / equity | 0.05 | 0.11 | 0.21 | 0.04 | 0.04 | 0.06 | — | — |
| Debt / assets | 0.05 | 0.09 | 0.15 | 0.03 | 0.03 | 0.04 | 0.18 | 0.02 |
| Current ratio | 10.47 | 7.53 | 4.73 | 5.88 | 4.88 | 2.73 | 2.69 | 8.92 |
| Quick ratio | 10.47 | 7.53 | 4.73 | 6.05 | 4.97 | 4.21 | 2.69 | 8.92 |
| Interest coverage | — | — | -844.5 | -916.2 | -574.5 | -402.6 | -917.5 | — |
| Working capital | $788.0M | $442.5M | $319.6M | $348.1M | $358.7M | $191.7M | $58.3M | $37.1M |
| Invested capital | $813.6M | $434.6M | $104.8M | $100.3M | $35.2M | $5.7M | −$145.2M | −$75.0M |
| Tangible asset value | $1.58B | $835.6M | $395.0M | $490.2M | $459.6M | $283.9M | −$74.4M | −$34.4M |
| Net current asset value | $708.1M | $367.9M | $224.5M | $306.4M | $305.0M | $99.1M | −$98.3M | −$36.9M |
| Graham net-net per share | $8.12 | $4.62 | $3.57 | $5.38 | $6.08 | $0.28 | −$2.22 | −$0.84 |
| Capital allocation | ||||||||
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | — | — |
| Dividends + buybacks / free cash flow | — | — | — | — | — | 0.0% | — | — |
| Capex / revenue | 3.7% | 27.3% | 43.9% | 6.1% | 2.2% | 26.7% | 18.1% | — |
| Capex / operating cash flow | — | — | — | — | — | 10.3% | 3.0% | — |
| Capex / depreciation | 0.17 | 1.74 | 9.67 | 0.95 | 0.67 | 5.16 | 0.64 | 6.61 |
| Stock-based compensation / revenue | 152.8% | 116.9% | 54.9% | 75.8% | 34.3% | 15.2% | 40.8% | — |
| R&D / revenue | 807.7% | 510.4% | 240.6% | 350.8% | 188.1% | 182.5% | 1,266.5% | — |
| SG&A / revenue | 174.0% | 135.0% | 70.0% | 93.6% | 49.9% | 53.6% | 272.0% | — |
| Efficiency | ||||||||
| Days sales outstanding | — | 76.4 | 49.5 | 10.4 | 3.9 | 9.2 | 27.1 | — |
| Days of inventory on hand | — | — | -11.8 | -1,302.1 | -13,124.2 | -960.2 | — | — |
| Days payables outstanding | — | 323.4 | 11.0 | 511.3 | 637.5 | 22.5 | 1,179.5 | 3,660.7 |
| Cash conversion cycle (days) | — | -247.0 | 26.6 | -1,802.9 | -13,757.8 | -973.5 | -1,152.4 | — |
| Receivables turnover | — | 4.78 | 7.38 | 35.05 | 92.90 | 39.57 | 13.49 | 0.00 |
| Payables turnover | 0.00 | 1.13 | 33.14 | 0.71 | 0.57 | 16.25 | 0.31 | 0.10 |
| Asset turnover | 0.03 | 0.06 | 0.13 | 0.08 | 0.13 | 0.11 | 0.04 | 0.00 |
| Average receivables | — | $9.9M | $10.6M | $1.3M | $784,000 | $860,000 | $217,500 | $148,000 |
| Average payables | $5.0M | $6.5M | $5.7M | $4.2M | $4.2M | $3.8M | $2.7M | $2.1M |
| Average inventory | — | — | −$6.1M | −$10.6M | −$86.2M | −$163.4M | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from KYMR's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
KYMR valuation and financial ratios
Kymera Therapeutics earned a return on equity of −25.8% and a return on invested capital of −44.2% in fiscal 2025. It ended the year with $82.3 million of debt and $848.3 million in cash and short-term investments, a net cash position of $766.0 million. The share count rose 89.5% from 44.5M to 84.4M over 7 years.
See the KYMR income statement, the KYMR chart for price history, or the KYMR stock overview for the latest quote and news.
KYMR key metrics FAQ
What is Kymera Therapeutics's return on equity?
Kymera Therapeutics's return on equity (ROE) was −25.8% in fiscal 2025: net income of -$311.4 million on average shareholders' equity of $1.2 billion.
What is Kymera Therapeutics's ROIC?
Kymera Therapeutics's return on invested capital was −44.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Kymera Therapeutics have?
Kymera Therapeutics had total debt of $82.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.05 and more cash than debt.
What is Kymera Therapeutics's free cash flow yield?
Kymera Therapeutics generated -$234.3 million of free cash flow in fiscal 2025, a free cash flow yield of −3.6% on its market value at year-end ($6.6 billion).
What is Kymera Therapeutics's current ratio?
Kymera Therapeutics's current ratio was 10.47 at the end of fiscal 2025: current assets were 10.47 times current liabilities.